MarketPulse

VK2735

9 articles
BenzingaBenzinga··Prnewswire

Viking Therapeutics to Report Q1 2026 Results; Obesity Drug VK2735 in Focus

Viking Therapeutics will report Q1 2026 earnings April 29 after market close, showcasing progress on obesity and metabolic disorder treatments.
VKTXfinancial resultsPhase 3 trials
BenzingaBenzinga··Prnewswire

Viking Therapeutics Expands Investor Outreach With Spring Conference Circuit

Viking Therapeutics to present at two major biotech conferences in April 2026, conducting investor meetings in New York and Boston.
VKTXinvestor conferencesclinical trials
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Viking Therapeutics' Billion-Dollar Bet: Can VK2735 Compete in the Weight-Loss Gold Rush?

Viking Therapeutics' VK2735 targets the $100+ billion weight-loss market. Success could drive massive stock appreciation, but clinical and competitive risks remain substantial.
LLYVKTXbiotechregulatory approval
The Motley FoolThe Motley Fool··Thomas Niel

Viking Therapeutics' VK2735 Could Reshape Weight Loss Market—If Phase 3 Succeeds

Viking Therapeutics' VK2735 could threaten Novo Nordisk and Eli Lilly's GLP-1 dominance if phase 3 trials succeed, triggering potential threefold gains or severe losses.
PFELLYNVOVKTXclinical trialsVK2735
BenzingaBenzinga··Prnewswire

Viking Therapeutics Completes Enrollment in Phase 3 VANQUISH-2 Obesity Trial

Viking Therapeutics finishes enrolling 1,000 patients in Phase 3 VANQUISH-2 trial of VK2735 for obesity treatment, with results expected in 2027.
VKTXPhase 3 clinical trialobesity treatment
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Viking Therapeutics Advances Weight-Loss Candidate Into Late-Stage Trials

Viking Therapeutics advances obesity drug VK2735 into Phase 3 trials after positive interim results, positioning itself in the competitive weight-loss pharmaceutical market.
LLYNVOVKTXbiotechweight loss drugs
BenzingaBenzinga··Vandana Singh

Viking Therapeutics Climbs on Competitive Positioning in Obesity Drug Race

Viking Therapeutics surged 10.91% after Novo Nordisk's obesity drug failed against Eli Lilly's competitor. Viking's dual injectable/oral candidate VK2735 offers differentiation entering Phase 3 trials.
LLYNVORHHBYVKTXPhase 3 trialsweight loss
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Positioned for Market Expansion as Obesity Drug Sector Scales

Viking Therapeutics poised for growth as obesity drug market expands to $100 billion by decade's end. VK2735's Phase 3 success could establish the company as a key competitor.
LLYNVOVKTXbiotechPhase 3 trial
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Advances Obesity Treatment Pipeline Ahead of 2026 Trial Milestones

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.
LLYNVOVKTXbiotechclinical trials